T Allan Darnell, MD
Public Health & General Preventive Medicine · Loma Linda, CANPI 1073695367
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Lilly USA, LLC at 49.4% of the total. 2025 is the largest year on record at $32, 2.4 times the $13 reported in 2019. That places this record below the midpoint for public health & general preventive medicine clinicians in CA, where the typical reported total is $132.
Across 3 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$32
- Dexcom, Inc.$19
- Novo Nordisk$13
Across 5 payments — averaging $53,222 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$266K
What the payments were for
- Food & beverage$64100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1 | $32 |
| Dexcom, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $13 |
How this compares
$64 in reported general payments places this provider in the 30th percentile of 109 public health & general preventive medicine providers in California.
See all public health & general preventive medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $37,153 |
| MounjaroTirzepatide | 17 | $18,063 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 30 | $1,705 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $1,497 |
| Bupropion XlBupropion Hcl | 12 | $983 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $667 |
| ProgesteroneProgesterone, Micronized | 11 | $411 |
| Losartan Potassium | 21 | $291 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $285 |
| Zolpidem Tartrate | 11 | $256 |
| Rosuvastatin Calcium | 13 | $167 |
| Levothyroxine Sodium | 22 | $150 |
| Azithromycin | 17 | $72 |
| Amlodipine Besylate | 11 | $70 |
| Atorvastatin Calcium | 24 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $13 | $37,15334 claims |
| Lilly USA, LLCMounjaro | $32 | $18,06317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 109 public health & general preventive medicine providers in California.
Other public health & general preventive medicine in Loma Linda
- Karen StuderLoma Linda$9K
- Serena TonstadLoma Linda$5K
- Peter BastianLoma Linda$554
- Tonya CramerLoma Linda$247
- Richel StrydomLoma Linda$163
- Aileen LoLoma Linda$158
- Steven GalsonThousand Oaks$594K
- Ryan ZaneSan Bernardino$97K
- Ross MillerBeverly Hills$65K
- Daniel CosgroveIndian Wells$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.